Genetic Causes of Intellectual Disability: Down, Fragile X, Rett Syndromes

Intellectual disability (ID) has diverse genetic etiologies. Three major syndromes illustrate different genetic mechanisms: chromosomal, single-gene X-linked, and X-linked dominant.

Chromosomal: Down Syndrome

Trisomy 21 (extra chromosome 21) → overexpression of ~300 genes → characteristic phenotype (intellectual disability, hypotonia, congenital heart defects, distinct facial features, increased leukemia risk). Most common genetic cause of ID (~1/700 births).

Single-Gene X-Linked: Fragile X Syndrome

Most common inherited cause of ID. CGG repeat expansion (>200 repeats, full mutation) in the FMR1 gene (Xq27.3) → methylation and transcriptional silencing → loss of FMRP (fragile X mental retardation protein) → dysregulated synaptic plasticity. X-linked dominant with variable expressivity; males typically more severely affected.

X-Linked Dominant: Rett Syndrome

MECP2 mutations (Xq28) → severe ID, developmental regression (6–18 months), hand stereotypies (hand-wringing), seizures, autonomic dysfunction, autism features. Almost exclusively females (lethal in most males).

Other Notable Single-Gene ID Syndromes

  • Angelman syndrome: Maternal 15q11-q13 deletion or UBE3A mutation → severe ID, happy demeanor, ataxia, seizures, absent speech.
  • Prader-Willi syndrome: Paternal 15q11-q13 deletion → neonatal hypotonia, hyperphagia/obesity, hypogonadism, mild-moderate ID.
  • Rubinstein-Taybi syndrome: CREBBP or EP300 mutations → ID, broad thumbs/toes, characteristic facies.

Diagnostic Approach

  • Chromosomal microarray (CMA): First-tier for global developmental delay/ID—detects CNVs.
  • Fragile X testing (PCR/Southern blot): Recommended for all males with unexplained ID; females with family history or clinical features.
  • Exome/genome sequencing: For nondiagnostic CMA/Fragile X; identifies single-gene disorders.
  • Targeted panels: For specific phenotypes (e.g., RASopathies, neurodevelopmental disorders).

Genetic diagnosis guides prognosis, recurrence risk counseling, syndrome-specific surveillance (e.g., cardiac in Down, seizure monitoring in Angelman), and access to targeted therapies/clinical trials.

Genetic Disorders - Related Articles